Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The thyroid hormones (THs) regulate various physiological mechanisms in mammals, such as cellular metabolism, cell structure, and membrane transport. The therapeutic drugs propylthiouracil (PTU) and phenytoin are known to induce hypothyroidism and decrease blood thyroid hormone levels. To analyze the impact of these two drugs on systemic metabolism, we focused on metabolic changes after treatment. Therefore, in a rat model, the metabolome of thyroid and liver tissue as well as from the blood plasma, after 2-week and 4-week administration of the drugs and after a following 2-week recovery phase, was investigated using targeted LC-MS/MS and GC-MS. Both drugs were tested at a low dose and a high dose. We observed decreases in THs plasma levels, and higher doses of the drugs were associated with a high decrease in TH levels. PTU administration had a more pronounced effect on TH levels than phenytoin. Both drugs had little or no influence on the metabolomes at low doses. Only PTU exhibited apparent metabolome alterations at high doses, especially concerning lipids. In plasma, acylcarnitines and triglycerides were detected at decreased levels than in the controls after 2- and 4-week exposure to the drug, while sphingomyelins and phosphatidylcholines were observed at increased levels. Interestingly, in the thyroid tissue, triglycerides were observed at increased concentrations in the 2-week exposure group to PTU, which was not observed in the 4-week exposure group and in the 4-week exposure group followed by the 2-week recovery group, suggesting an adaptation by the thyroid tissue. In the liver, no metabolites were found to have significantly changed. After the recovery phase, the thyroid, liver, and plasma metabolomic profiles showed little or no differences from the controls. In conclusion, although there were significant changes observed in several plasma metabolites in PTU/Phenytoin exposure groups, this study found that only PTU exposure led to adaptation-dependent changes in thyroid metabolites but did not affect hepatic metabolites.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383188PMC
http://dx.doi.org/10.3390/metabo13070847DOI Listing

Publication Analysis

Top Keywords

thyroid liver
12
4-week exposure
12
exposure group
12
thyroid
8
liver plasma
8
2-week recovery
8
recovery phase
8
observed increased
8
thyroid tissue
8
plasma
6

Similar Publications

Rationale: Brown tumor (osteitis fibrosa cystica) is a benign bone lesion associated with hyperparathyroidism that can affect multiple bones in patients with end-stage renal disease (ESRD).

Patient Concerns: We present the case of a 32-year-old female with ESRD on maintenance hemodialysis who experienced body aches, muscle weakness, constipation, and mood swings for 3 months.

Diagnoses: Initial tests revealed elevated parathyroid hormone (PTH), serum calcium, and phosphorus levels.

View Article and Find Full Text PDF

Survivin, an inhibitor of apoptosis protein, is minimally expressed in normal adult tissues but overexpressed in multiple cancers. This study investigates survivin expression alongside autophagy markers ATG7 and LC3B in seven solid tumor types in Indian patient samples. Immunohistochemical analysis was performed on 48 cancer tissue samples (breast n = 7, buccal n = 6, cervical n = 5, colon n = 8, renal n = 6, liver n = 10, thyroid n = 6) and adjacent normal tissues (n = 9) using anti-human antibodies against survivin, ATG7, and LC3B.

View Article and Find Full Text PDF

Introduction: To examine the association of the number of controlled risk factors with the excess risk of severe metabolic dysfunction-associated steatotic liver disease (MASLD) and major adverse liver outcomes (MALO) among patients with type 2 diabetes.

Research Design And Methods: In this cohort study, a total of 307,688 participants from the UK Biobank were included. Participants with baseline type 2 diabetes were categorized according to the number of risk factors within the guideline-recommended ranges (diet, smoking, drinking, exercise, sedentary behavior, body mass index, glycated hemoglobin, blood pressure, and low-density lipoprotein cholesterol).

View Article and Find Full Text PDF

Systemic Toxicity of L-Mimosine in Rabbits: A Non-Rodent Model for Safety Assessment.

J Appl Toxicol

September 2025

Research Centre for Veterinary Toxicology (CEPTOX) - Department of Pathology, School of Veterinary Medicine and Animal Sciences, University of São Paulo, Pirassununga, SP, Brazil.

L-mimosine is a non-protein amino acid primarily found in the Mimosoideae subfamily, with high concentrations in Leucaena leucocephala and Mimosa pudica. These plants are widely used in both human and animal nutrition, as well as in phytotherapeutic applications. While the toxic effects of L-mimosine have been extensively studied in ruminants, its impact on monogastric species remains unexplored.

View Article and Find Full Text PDF

Semaglutide, a GLP-1 receptor agonist, is FDA-approved for managing type 2 diabetes (T2D) and reducing cardiovascular risk. Its off-label use in weight management and other conditions has grown, prompting a review of its benefits and risks. This review evaluates evidence on semaglutide's effects, highlighting its therapeutic potential beyond approved indications.

View Article and Find Full Text PDF